Barclays PLC Purchases 128,246 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Barclays PLC boosted its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 162.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 207,309 shares of the company's stock after acquiring an additional 128,246 shares during the quarter. Barclays PLC owned 0.20% of Dyne Therapeutics worth $7,446,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in DYN. FMR LLC grew its holdings in shares of Dyne Therapeutics by 69.7% in the 3rd quarter. FMR LLC now owns 9,026,697 shares of the company's stock worth $324,239,000 after purchasing an additional 3,707,734 shares during the last quarter. RTW Investments LP boosted its position in Dyne Therapeutics by 6.8% in the third quarter. RTW Investments LP now owns 6,818,641 shares of the company's stock valued at $244,926,000 after buying an additional 431,503 shares in the last quarter. Janus Henderson Group PLC grew its stake in Dyne Therapeutics by 47.3% during the third quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company's stock worth $244,755,000 after buying an additional 2,189,339 shares during the last quarter. RA Capital Management L.P. increased its holdings in shares of Dyne Therapeutics by 5.5% during the third quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company's stock worth $229,211,000 after buying an additional 331,940 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Dyne Therapeutics by 13.8% in the third quarter. State Street Corp now owns 3,641,859 shares of the company's stock valued at $130,816,000 after acquiring an additional 440,890 shares during the last quarter. Institutional investors own 96.68% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Robert W. Baird started coverage on shares of Dyne Therapeutics in a report on Friday, December 13th. They set an "outperform" rating and a $46.00 price objective on the stock. Royal Bank of Canada assumed coverage on shares of Dyne Therapeutics in a research note on Tuesday, November 26th. They set an "outperform" rating and a $45.00 price target on the stock. HC Wainwright restated a "buy" rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. Piper Sandler reiterated an "overweight" rating and issued a $53.00 price objective on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Finally, StockNews.com downgraded Dyne Therapeutics from a "hold" rating to a "sell" rating in a research report on Monday, September 16th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $50.42.

Dyne Therapeutics Trading Down 1.1 %

Shares of NASDAQ:DYN traded down $0.26 during mid-day trading on Thursday, reaching $24.30. The stock had a trading volume of 923,789 shares, compared to its average volume of 1,437,750. The firm has a 50 day simple moving average of $29.99 and a two-hundred day simple moving average of $35.11. Dyne Therapeutics, Inc. has a twelve month low of $11.66 and a twelve month high of $47.45. The firm has a market cap of $2.47 billion, a PE ratio of -6.83 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.25). On average, equities analysts anticipate that Dyne Therapeutics, Inc. will post -3.45 EPS for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In related news, insider Oxana Beskrovnaya sold 2,334 shares of the stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $65,632.08. Following the completion of the transaction, the insider now directly owns 201,685 shares in the company, valued at approximately $5,671,382.20. This trade represents a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Dirk Kersten sold 79,411 shares of Dyne Therapeutics stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $36.45, for a total transaction of $2,894,530.95. Following the completion of the sale, the director now owns 234,127 shares in the company, valued at $8,533,929.15. This trade represents a 25.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 167,341 shares of company stock valued at $5,862,564. Company insiders own 20.77% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.